文献速递慢阻肺

心肌梗死后慢阻肺患者使用β受体阻滞剂与急性加重风险:丹麦全国队列研究

Beta-blocker use and acute exacerbations of COPD following myocardial infarction: a Danish nationwide cohort study.
PubMed 文献 · Thorax · 2020-08-20

结果显示,β受体阻滞剂使用与AECOPD风险降低相关(多变量校正HR 0.78,95%CI 0.74-0.83),且该关联不受心梗类型、心力衰竭、剂量、类型及加重严重程度影响,在重度慢阻肺和高频加重患者中结果一致。

要点

  • 心梗后慢阻肺患者使用β受体阻滞剂与AECOPD风险降低相关,不支持因担心加重而停用。
  • 该获益在STEMI和非STEMI、伴或不伴心衰、不同剂量和类型中均一致。
  • 在重度慢阻肺及频繁加重的高危患者中,β受体阻滞剂仍与AECOPD风险降低相关。

核心结论

  • 心肌梗死后慢阻肺患者使用β受体阻滞剂与AECOPD风险降低相关,而非增加风险。

研究设计与样本

  • 采用多变量、时间依赖性Cox回归,根据处方报销记录动态评估β受体阻滞剂使用。

主要发现

  • 1年AECOPD发生率为35%,1年时65%的患者使用β受体阻滞剂。
  • β受体阻滞剂使用与AECOPD风险降低相关(多变量校正HR 0.78,95%CI 0.74-0.83)。
  • STEMI中HR 0.70(95%CI 0.59-0.83),非STEMI中HR 0.80(95%CI 0.75-0.84)。
  • 伴心衰者HR 0.82(95%CI 0.74-0.90),不伴心衰者HR 0.77(95%CI 0.72-0.82)。
  • 在1118例有完整慢阻肺严重度和症状数据的患者(中位FEV1占预计值46%,多数中度呼吸困难)及1358例重度慢阻肺频繁加重患者(1年AECOPD率70%)中结果相似。

临床怎么用

  • 心梗后慢阻肺患者不应因担心AECOPD而停用或避免β受体阻滞剂。
  • 重度慢阻肺及频繁加重的高危患者使用β受体阻滞剂同样与AECOPD风险降低相关。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Patients with chronic obstructive pulmonary disease (COPD) are undertreated with beta-blockers following myocardial infarction (MI), possibly due to fear for acute exacerbations of COPD (AECOPD). Is beta-blocker use associated with increased risk of AECOPD in patients following first-time MI? METHODS: Danish nationwide study of patients with COPD following hospitalisation for MI from 2003 to 2015. Multivariable, time-dependent Cox regression accounting for varying beta-blocker use based on claimed prescriptions during up to 13 years of follow-up. RESULTS: A total of 10 884 patients with COPD were discharged after first-time MI. The 1-year rate of AECOPD was 35%, and 65% used beta-blockers at 1 year. Beta-blocker use was associated with a lower risk of AECOPD (multivariable-adjusted HR 0.78, 95% CI 0.74-0.83). This association was independent of the type of MI (HR 0.70, 95% CI 0.59-0.83 in ST-elevation MI (STEMI) and HR 0.80, 95% CI 0.75-0.84 in non-STEMI), presence or absence of heart failure (HR 0.82, 95% CI 0.74-0.90 and HR 0.77, 95% CI 0.72-0.82, respectively), beta-blocker dosage and type, as well as exacerbation severity. Results were similar in 1118 patients with full data on COPD severity and symptom burden (median forced expiratory volume in 1 s as percentage of predicted was 46 and majority had moderate dyspnoea), and in 1358 patients with severe COPD and frequent AECOPD with a high 1-year rate of AECOPD of 70%. DISCUSSION: Beta-blocker use was not associated with increased risk of AECOPD following MI. This finding was independent of COPD severity, symptom burden and exacerbation history, and supports the safety of beta-blockers in patients with COPD, including high-risk patients with severe disease.

来源:Thorax,查看原文。版权归原作者所有。

引用

  1. Rasmussen DB, Bodtger U, Lamberts M, et al. Beta-blocker use and acute exacerbations of COPD following myocardial infarction: a Danish nationwide cohort study. Thorax. 2020. PMID: 32820080. doi:10.1136/thoraxjnl-2019-214206

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。